Search Results 61-70 of 16606 for villous atrophy

1. A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration - Mayo Clinic

   The purposes of this study are to find out whether danicopan can slow the rate of geographic atrophy (GA) disease progression and slow the loss of visual ...

2. Study to Evaluate the Pathophysiology of Multiple System Atrophy, Parkinson's Disease, Parkinson's Disease with Autonomic Failure and Dementia with Lewy Bodies Using Microneurographic Recordings of Muscle Sympathetic Nerve Activity - Mayo Clinic

   Study to Evaluate the Pathophysiology of Multiple System Atrophy, Parkinson's Disease, Parkinson's Disease with Autonomic Failure and Dementia with Lewy Bodies ...

3. Lu AF82422 in participants with Multiple System Atrophy - Mayo Clinic

   The purpose of this study is to evaluate the efficacy and safety of Lu AF82422 for the treatment of MSA. Participation eligibility. Participant eligibility ...

4. Doctors and departments - Mayo Clinic

   Multiple system atrophy. Departments and specialties. Mayo Clinic has one of the largest and most experienced practices in the United States, with campuses in ...

5. Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients - Mayo Clinic

   Any change in duodenal villous architecture consistent with celiac disease (e.g., atrophy ... villous atrophy despite a strict GFD for more than 12 months).

6. A Study of Lu AF82422 in participants with Multiple System Atrophy - Mayo Clinic

   The purpose of this study is to evaluate the efficacy and safety of Lu AF82422 for the treatment of MSA. Participation eligibility. Participant eligibility ...

7. Villitis of unknown etiology found to be distinct placental condition negatively impacting the fetus, requiring screening and treatment - Mayo Clinic

   Maternal T cells in the human placental villi support an allograft response during noninfectious villitis. The Journal of Immunology. 2020;204:2931. Chen A ...

8. A Study to Assess the Safety and Tolerability of Single and Multiple Doses of KAN-101 in Celiac Disease Patients - Mayo Clinic

   ... villous atrophy. Has HLA-DQ2.5 genotype (HLA-DQA1*05 and HLA-DQB1*02) (homozygotes or heterozygotes). Has followed a GFD for > 12 months immediately prior ...

9. A Study to Identify Biomarkers of Spinal Muscular Atrophy in Spinraza-Treated Patients - Mayo Clinic

   Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...

10. Predicting Intestinal Healing in Celiac Disease

    Hello, my name is Joe Murray. I'm a gastroenterologist in the Celiac Disease Program at Mayo Clinic. One of the challenges of following our patients with ...